Tratamiento de la insuficiencia cardiaca: la cuenta atrás empieza en el momento del diagnóstico

Antonio García Quintana, María del Val Groba Marco, Mario Galván Ruíz
{"title":"Tratamiento de la insuficiencia cardiaca: la cuenta atrás empieza en el momento del diagnóstico","authors":"Antonio García Quintana,&nbsp;María del Val Groba Marco,&nbsp;Mario Galván Ruíz","doi":"10.1016/S1131-3587(20)30003-0","DOIUrl":null,"url":null,"abstract":"<div><p>Clinical trials have found that sacubitril–valsartan is effective in reducing the risk of hospitalization and death from heart failure and real-life data have confirmed the drug combination’s effectiveness and safety. Moreover, early use during hospitalization, in both patients with de novo heart failure and previously untreated patients, also appears to be safe and is recommended for simplifying patient management and easing transitional care. In addition, sacubitril-valsartan has a beneficial effect on cardiac remodeling, as demonstrated by the results of the PROVE-HF study, which is greater with an early onset and at higher doses in observational studies.</p><p>Supplement information: this article is part of a supplement entitled “Questions on a new era for heart failure treatment” which is sponsored by Novartis</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Cardiologia Suplementos","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1131358720300030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Clinical trials have found that sacubitril–valsartan is effective in reducing the risk of hospitalization and death from heart failure and real-life data have confirmed the drug combination’s effectiveness and safety. Moreover, early use during hospitalization, in both patients with de novo heart failure and previously untreated patients, also appears to be safe and is recommended for simplifying patient management and easing transitional care. In addition, sacubitril-valsartan has a beneficial effect on cardiac remodeling, as demonstrated by the results of the PROVE-HF study, which is greater with an early onset and at higher doses in observational studies.

Supplement information: this article is part of a supplement entitled “Questions on a new era for heart failure treatment” which is sponsored by Novartis

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心力衰竭的治疗:从诊断的那一刻开始倒计时
临床试验发现,苏比替-缬沙坦可有效降低因心力衰竭住院和死亡的风险,实际数据也证实了该药物组合的有效性和安全性。此外,住院期间的早期使用,无论是新发心力衰竭患者还是先前未治疗的患者,似乎也是安全的,建议用于简化患者管理和缓解过渡性护理。此外,正如PROVE-HF研究结果所证明的那样,苏比替-缬沙坦对心脏重构具有有益作用,在观察性研究中,早起效和高剂量的作用更大。补充信息:本文是由诺华赞助的题为“关于心力衰竭治疗新时代的问题”的补充的一部分
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Revista Espanola de Cardiologia Suplementos
Revista Espanola de Cardiologia Suplementos Medicine-Cardiology and Cardiovascular Medicine
CiteScore
1.20
自引率
0.00%
发文量
1
期刊介绍: Revista Española de Cardiología, is an international scientific journal dealing with cardiovascular medicine. Revista Española de Cardiología, the official publication of the Spanish Society of Cardiology, publishes research articles related to cardiovascular diseases. Articles are published in Spanish for the paper edition and in both Spanish and English in the electronic edition, which is available on the Internet. Regular sections include original articles reporting clinical or basic research, brief reports, review articles, editorials and letters to the Editor.
期刊最新文献
Riesgo residual. Conclusiones Consideraciones clínicas y estrategias terapéuticas para reducir el riesgo residual Icosapento de etilo en la disminución del riesgo residual. Nuevas evidencias Recomendaciones actuales de las guías respecto al riesgo residual ¿Qué es el riesgo cardiovascular residual? Etiología, lípidos e inflamación
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1